경경정맥간내문맥정맥단락술 시장 : 디바이스 유형별, 용도별, 최종 사용자별 - 세계 기회 분석 및 산업 예측(2021-2031년)

The global transjugular intrahepatic portosystemic shunt (TIPS) market was valued at $93,370.5 thousand in 2021, and is projected to reach $127,937.57 thousand by 2031, registering a CAGR of 3.2% from 2022 to 2031.

Transjugular intrahepatic portosystemic shunt (TIPS) is an artificial passage that allows fluid to move from one part of the liver to another. It connects veins that carry blood from gastrointestinal tract and intra-abdominal organs to liver and veins from liver to right part of the heart. In this procedure a small metal device, which is called stent is placed to keep connection of vein and liver. Doctor inserts a catheter, which is a flexible tube through skin into the vein of neck. This vein is known as jugular vein. Transjugular intrahepatic portosystemic shunt reduces internal bleeding in stomach and may also reduce accumulation of fluid in the abdomen. This procedure is done by interventional radiologists using x-ray guidance.

Growth of the transjugular intrahepatic portosystemic shunt market is supported by rise in cases of portal hypertension and increase in adoption of transjugular intrahepatic portosystemic shunts to minimize barriers. In addition, constantly changing lifestyle habits (such as unhealthy dietary habits, excessive alcohol consumption, smoking, obesity, and lack of physical activity) make individuals more susceptible to liver failure. In addition, a number of factors such as a large number of technological advancements in transjugular intrahepatic portosystemic shunt and rise in emphasis on early intervention and primary prevention of liver related disorders are responsible for driving the market growth. Moreover, rise in demand and adoption of products such as stent, catheters, sheath and guidewires and launch of transjugular intrahepatic portosystemic shunt devices by large number of key players are the major factors driving the market growth. Furthermore, according to the World Health Organization, in 2019, approximately 1.28 billion people suffered from hypertension, which is the main cause of death. Thus, rise in number of cases of people suffering from hypertension leads to increase in use of transjugular intrahepatic portosystemic shunt drives growth of the market. Moreover, surge in incidences of emergency surgeries and growing adoption of vascular devices propel growth of the transjugular intrahepatic portosystemic shunt (TIPS) market. Liver disease causes damage of liver and leads to cirrhosis.

According to the report by the Gov.UK in 2021, it was estimated that there were approximately 10,127 deaths due to liver disease in England and it increased as compared to 2019. Moreover, the number of rate of people died in England due to liver disease was 20.6 per 100,000 population with ages under 75. In addition, according to the National Center for Disease Control and Prevention in 2020, it was estimated that mortality rate of cirrhosis was 7.0% in New York, with approximately 1,672 number of deaths. Thus, rising number of cases suffering from cirrhosis led to increase in usage of transjugular intrahepatic portosystemic shunt devices for treatment that significantly drive growth of the market. For instance, in 2019, it was estimated that approximately 820,000 people died due to cirrhosis and hepatocellular carcinoma globally. Thus, rising number of cases of cirrhosis leads to higher demand among people. Hence, usage of transjugular intrahepatic portosystemic shunt (TIPS) fuel the growth of the market. Moreover, development of medical device industries and improvement in healthcare spending are anticipated to drive growth of the transjugular intrahepatic portosystemic shunt (TIPS) market. 

For instance, in June 2022, Boston Scientific Corporation entered into definitive agreement with Synergy Innovation Co. Ltd. to purchase its majority stake of M.I. Tech Co., Ltd., Korean manufacturer and distributor of medical devices for endoscopic and urologic procedures. M.I Tech Co. Ltd is the creator of the HANAROSTENT technology, a non-vascular self-expanding metal stent. Non-vascular gastrointestinal stents are used to help treat occlusions in various areas of gastrointestinal tract. Thus, rising number of strategies such as agreement and acquisitions among key players drive growth of the market.

Furthermore, rise in geriatric population and increase in burden of liver diseases lead to rise in awareness regarding transjugular intrahepatic portosystemic shunt treatment among people, which drive growth of the market. Moreover, according to the American Liver foundation in 2020, it was estimated that approximately 51,642 adults in the U.S died due to liver disease and 4.5 million adults have been diagnosed with the disease. Moreover, The American Liver Foundation is the largest non-profit organization focused solely on promoting liver health and disease prevention.

The American Liver Foundation fights against liver disease by funding scientific research and support programs for patients with liver disease and their families as well as creating public awareness by launching various awareness campaigns about liver wellness and disease prevention. Thus, rising number of cases of liver diseases in the U.S and other countries and initiatives taken by private and government healthcare organizations to prevent liver disorders drive growth of the global market. Moreover, increase in healthcare expenditure in emerging economies and high demand for minimally invasive procedures are expected to provide new opportunities for market players. However, lack of awareness in developing regions is anticipated to hamper the market growth.

The transjugular intrahepatic portosystemic shunt (TIPS) market is studied by device type, which is divided into stents and accessories and by application, which is fragmented into portal hypertension, Budd-Chiari Syndrome, and others. By end user, it is categorized into hospitals, specialty clinics, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The key players mentioned in the report are Boston Scientific Corporation, W.L Gore Associated Ltd, Angiodynamics, and Neuromedex GmbH, and Cook Medical, Becton Dickinson and Company, and Terumo Medical Corporation.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the transjugular intrahepatic portosystemic shunt (tips) market analysis from 2021 to 2031 to identify the prevailing transjugular intrahepatic portosystemic shunt (tips) market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the transjugular intrahepatic portosystemic shunt (tips) market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global transjugular intrahepatic portosystemic shunt (tips) market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By End User

• Hospitals
• Specialty Clinics
• Others

By Device Type

• Stents
• Accessories

By Application

• Portal hypertension
• Budd Chiari Syndrome
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest Of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest Of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest Of LAMEA
• Key Market Players
  • Boston Scientific Corporation
  • W. L. Gore & Associates, Inc. 
  • Cook
  • BD
  • AngioDynamics Inc.
  • Neuromedex GmbH
  • Terumo Medical Corporation
  • Company 8
  • Company 9
  • Company 10

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key market segments
• 1.3.Key benefits to the stakeholders
• 1.4.Research Methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
• 3.3.Porter's five forces analysis
• 3.4.Top player positioning
• 3.5.Market dynamics
  • 3.5.1.Drivers
  • 3.5.2.Restraints
  • 3.5.3.Opportunities
• 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY DEVICE TYPE

• 4.1 Overview
  • 4.1.1 Market size and forecast
• 4.2 Stents
  • 4.2.1 Key market trends, growth factors and opportunities
  • 4.2.2 Market size and forecast, by region
  • 4.2.3 Market analysis by country
• 4.3 Accessories
  • 4.3.1 Key market trends, growth factors and opportunities
  • 4.3.2 Market size and forecast, by region
  • 4.3.3 Market analysis by country

CHAPTER 5: TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY APPLICATION

• 5.1 Overview
  • 5.1.1 Market size and forecast
• 5.2 Portal hypertension
  • 5.2.1 Key market trends, growth factors and opportunities
  • 5.2.2 Market size and forecast, by region
  • 5.2.3 Market analysis by country
• 5.3 Budd Chiari Syndrome
  • 5.3.1 Key market trends, growth factors and opportunities
  • 5.3.2 Market size and forecast, by region
  • 5.3.3 Market analysis by country
• 5.4 Others
  • 5.4.1 Key market trends, growth factors and opportunities
  • 5.4.2 Market size and forecast, by region
  • 5.4.3 Market analysis by country

CHAPTER 6: TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY END USER

• 6.1 Overview
  • 6.1.1 Market size and forecast
• 6.2 Hospitals
  • 6.2.1 Key market trends, growth factors and opportunities
  • 6.2.2 Market size and forecast, by region
  • 6.2.3 Market analysis by country
• 6.3 Specialty Clinics
  • 6.3.1 Key market trends, growth factors and opportunities
  • 6.3.2 Market size and forecast, by region
  • 6.3.3 Market analysis by country
• 6.4 Others
  • 6.4.1 Key market trends, growth factors and opportunities
  • 6.4.2 Market size and forecast, by region
  • 6.4.3 Market analysis by country

CHAPTER 7: TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) MARKET, BY REGION

• 7.1 Overview
  • 7.1.1 Market size and forecast
• 7.2 North America
  • 7.2.1 Key trends and opportunities
  • 7.2.2 North America Market size and forecast, by Device Type
  • 7.2.3 North America Market size and forecast, by Application
  • 7.2.4 North America Market size and forecast, by End User
  • 7.2.5 North America Market size and forecast, by country
    • 7.2.5.1 U.S.
    • 7.2.5.1.1 Market size and forecast, by Device Type
    • 7.2.5.1.2 Market size and forecast, by Application
    • 7.2.5.1.3 Market size and forecast, by End User
    • 7.2.5.2 Canada
    • 7.2.5.2.1 Market size and forecast, by Device Type
    • 7.2.5.2.2 Market size and forecast, by Application
    • 7.2.5.2.3 Market size and forecast, by End User
    • 7.2.5.3 Mexico
    • 7.2.5.3.1 Market size and forecast, by Device Type
    • 7.2.5.3.2 Market size and forecast, by Application
    • 7.2.5.3.3 Market size and forecast, by End User
• 7.3 Europe
  • 7.3.1 Key trends and opportunities
  • 7.3.2 Europe Market size and forecast, by Device Type
  • 7.3.3 Europe Market size and forecast, by Application
  • 7.3.4 Europe Market size and forecast, by End User
  • 7.3.5 Europe Market size and forecast, by country
    • 7.3.5.1 Germany
    • 7.3.5.1.1 Market size and forecast, by Device Type
    • 7.3.5.1.2 Market size and forecast, by Application
    • 7.3.5.1.3 Market size and forecast, by End User
    • 7.3.5.2 France
    • 7.3.5.2.1 Market size and forecast, by Device Type
    • 7.3.5.2.2 Market size and forecast, by Application
    • 7.3.5.2.3 Market size and forecast, by End User
    • 7.3.5.3 UK
    • 7.3.5.3.1 Market size and forecast, by Device Type
    • 7.3.5.3.2 Market size and forecast, by Application
    • 7.3.5.3.3 Market size and forecast, by End User
    • 7.3.5.4 Italy
    • 7.3.5.4.1 Market size and forecast, by Device Type
    • 7.3.5.4.2 Market size and forecast, by Application
    • 7.3.5.4.3 Market size and forecast, by End User
    • 7.3.5.5 Spain
    • 7.3.5.5.1 Market size and forecast, by Device Type
    • 7.3.5.5.2 Market size and forecast, by Application
    • 7.3.5.5.3 Market size and forecast, by End User
    • 7.3.5.6 Rest of Europe
    • 7.3.5.6.1 Market size and forecast, by Device Type
    • 7.3.5.6.2 Market size and forecast, by Application
    • 7.3.5.6.3 Market size and forecast, by End User
• 7.4 Asia-Pacific
  • 7.4.1 Key trends and opportunities
  • 7.4.2 Asia-Pacific Market size and forecast, by Device Type
  • 7.4.3 Asia-Pacific Market size and forecast, by Application
  • 7.4.4 Asia-Pacific Market size and forecast, by End User
  • 7.4.5 Asia-Pacific Market size and forecast, by country
    • 7.4.5.1 Japan
    • 7.4.5.1.1 Market size and forecast, by Device Type
    • 7.4.5.1.2 Market size and forecast, by Application
    • 7.4.5.1.3 Market size and forecast, by End User
    • 7.4.5.2 China
    • 7.4.5.2.1 Market size and forecast, by Device Type
    • 7.4.5.2.2 Market size and forecast, by Application
    • 7.4.5.2.3 Market size and forecast, by End User
    • 7.4.5.3 Australia
    • 7.4.5.3.1 Market size and forecast, by Device Type
    • 7.4.5.3.2 Market size and forecast, by Application
    • 7.4.5.3.3 Market size and forecast, by End User
    • 7.4.5.4 India
    • 7.4.5.4.1 Market size and forecast, by Device Type
    • 7.4.5.4.2 Market size and forecast, by Application
    • 7.4.5.4.3 Market size and forecast, by End User
    • 7.4.5.5 South Korea
    • 7.4.5.5.1 Market size and forecast, by Device Type
    • 7.4.5.5.2 Market size and forecast, by Application
    • 7.4.5.5.3 Market size and forecast, by End User
    • 7.4.5.6 Rest of Asia-Pacific
    • 7.4.5.6.1 Market size and forecast, by Device Type
    • 7.4.5.6.2 Market size and forecast, by Application
    • 7.4.5.6.3 Market size and forecast, by End User
• 7.5 LAMEA
  • 7.5.1 Key trends and opportunities
  • 7.5.2 LAMEA Market size and forecast, by Device Type
  • 7.5.3 LAMEA Market size and forecast, by Application
  • 7.5.4 LAMEA Market size and forecast, by End User
  • 7.5.5 LAMEA Market size and forecast, by country
    • 7.5.5.1 Brazil
    • 7.5.5.1.1 Market size and forecast, by Device Type
    • 7.5.5.1.2 Market size and forecast, by Application
    • 7.5.5.1.3 Market size and forecast, by End User
    • 7.5.5.2 Saudi Arabia
    • 7.5.5.2.1 Market size and forecast, by Device Type
    • 7.5.5.2.2 Market size and forecast, by Application
    • 7.5.5.2.3 Market size and forecast, by End User
    • 7.5.5.3 South Africa
    • 7.5.5.3.1 Market size and forecast, by Device Type
    • 7.5.5.3.2 Market size and forecast, by Application
    • 7.5.5.3.3 Market size and forecast, by End User
    • 7.5.5.4 Rest of LAMEA
    • 7.5.5.4.1 Market size and forecast, by Device Type
    • 7.5.5.4.2 Market size and forecast, by Application
    • 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

• 9.1 Boston Scientific Corporation
  • 9.1.1 Company overview
  • 9.1.2 Company snapshot
  • 9.1.3 Operating business segments
  • 9.1.4 Product portfolio
  • 9.1.5 Business performance
  • 9.1.6 Key strategic moves and developments
• 9.2 W. L. Gore & Associates, Inc. 
  • 9.2.1 Company overview
  • 9.2.2 Company snapshot
  • 9.2.3 Operating business segments
  • 9.2.4 Product portfolio
  • 9.2.5 Business performance
  • 9.2.6 Key strategic moves and developments
• 9.3 Cook
  • 9.3.1 Company overview
  • 9.3.2 Company snapshot
  • 9.3.3 Operating business segments
  • 9.3.4 Product portfolio
  • 9.3.5 Business performance
  • 9.3.6 Key strategic moves and developments
• 9.4 BD
  • 9.4.1 Company overview
  • 9.4.2 Company snapshot
  • 9.4.3 Operating business segments
  • 9.4.4 Product portfolio
  • 9.4.5 Business performance
  • 9.4.6 Key strategic moves and developments
• 9.5 AngioDynamics Inc.
  • 9.5.1 Company overview
  • 9.5.2 Company snapshot
  • 9.5.3 Operating business segments
  • 9.5.4 Product portfolio
  • 9.5.5 Business performance
  • 9.5.6 Key strategic moves and developments
• 9.6 Neuromedex GmbH
  • 9.6.1 Company overview
  • 9.6.2 Company snapshot
  • 9.6.3 Operating business segments
  • 9.6.4 Product portfolio
  • 9.6.5 Business performance
  • 9.6.6 Key strategic moves and developments
• 9.7 Terumo Medical Corporation
  • 9.7.1 Company overview
  • 9.7.2 Company snapshot
  • 9.7.3 Operating business segments
  • 9.7.4 Product portfolio
  • 9.7.5 Business performance
  • 9.7.6 Key strategic moves and developments
• 9.8 Company 8
  • 9.8.1 Company overview
  • 9.8.2 Company snapshot
  • 9.8.3 Operating business segments
  • 9.8.4 Product portfolio
  • 9.8.5 Business performance
  • 9.8.6 Key strategic moves and developments
• 9.9 Company 9
  • 9.9.1 Company overview
  • 9.9.2 Company snapshot
  • 9.9.3 Operating business segments
  • 9.9.4 Product portfolio
  • 9.9.5 Business performance
  • 9.9.6 Key strategic moves and developments
• 9.10 Company 10
  • 9.10.1 Company overview
  • 9.10.2 Company snapshot
  • 9.10.3 Operating business segments
  • 9.10.4 Product portfolio
  • 9.10.5 Business performance
  • 9.10.6 Key strategic moves and developments